Dimebutic acid clinical trials
Also written HQK-1001.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses dimebutic acid is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
HemaQuest Pharmaceuticals Inc. (5) · Boston University (2)
Studies
Open first, then newest update. How each study uses dimebutic acid is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Effects of HQK-1001 in Patients With Sickle Cell DiseaseTerminatedPhase 2HemaQuest Pharmaceuticals Inc.NCT01601340Written as HQK-1001How we know
- A Study of HQK-1001 in Patients With Sickle Cell DiseaseCompletedPhase 2HemaQuest Pharmaceuticals Inc.NCT01322269Written as HQK-1001How we know
- Trial of HQK-1001 in Beta Thalassemia Intermedia in LebanonCompletedPhase 2Boston UniversityNCT01642758Written as Sodium 2,2 dimethylbutyrateHow we know
- Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in ThailandCompletedPhase 2Boston UniversityNCT01609595Written as sodium 2,2 dimethylbutyrateHow we know
- Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell DiseaseCompletedPhase 1/2HemaQuest Pharmaceuticals Inc.NCT00842088Written as HQK-1001How we know
- Phase 1/2 Study of HQK-1001 in Patients With Beta ThalassemiaCompletedPhase 1/2HemaQuest Pharmaceuticals Inc.NCT00790127Written as HQK-1001How we know
- Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy SubjectsCompletedPhase 1HemaQuest Pharmaceuticals Inc.NCT00717262Written as HQK-1001How we know
Codes
What other systems call dimebutic acid · ClinicalTrials.gg INT003634
- UNII (FDA) AY606CN05ODIMEBUTIC ACIDConfirmed FDA, NLM
- NCI Thesaurus C190420Dimebutic AcidOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AY606CN05O | DIMEBUTIC ACID | Confirmed FDA, NLM |
| NCI Thesaurus | C190420 | Dimebutic Acid | One source FDA |
Also registered as sodium 2,2-dimethylbutyrate (UNII XKM99SPB5I).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.